Prodrugs pp 1323-1334 | Cite as

Case Study: Oseltamivir: An Orally Bioavailable Ester Prodrug of Oseltamivir Carboxylate

  • Eugene J. Eisenberg
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume V)


Oseltamivir is an ethyl ester prodrug requiring ester hydrolysis for conversion to the active form, oseltamivir carboxylate, which is a potent carbocyclic transition-state analog inhibitor of influenza virus neuraminidase with activity against both influenza A and B viruses in vitro. The proposed mechanism of action of oseltamivir carboxylate is via inhibition of influenza virus neuraminidase by alteration of virus particle aggregation and release.


Influenza Virus Shikimic Acid Influenza Virus Infection H5N1 Influenza Virus Neuraminidase Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abbott A, and Pearson H, A. Fear of Human Pandemic Grows as Bird Flu Sweeps through Asia. Nature 2004; 427:472A–473ACrossRefGoogle Scholar
  2. Abdel-Magid AF, Maryanoff CA, and Mehrman SJ. Synthesis of Influenza Neuraminidase Inhibitors. Curr Opin Drug Discov Devel 2001; 4:776–791PubMedGoogle Scholar
  3. Assaad F, Bektimirov T, and Esteves KL. Influenza World Experience. In: Stuart-Harris CH. The Molecular Virology and Epidemiology of Influenza. London: Academic Press; 1984:5–38Google Scholar
  4. Babu YS, Chand P, Bantia S, Kotian P, Dehghani A, El Kattan Y, Lin TH, Hutchison TL, Elliott AJ, Parker CD, Ananth SL, Horn LL, Laver GW, and Montgomery JA. BCX-1812 (RWJ-270201): Discovery of a Novel, Highly Potent, Orally Active, and Selective Influenza Neuraminidase Inhibitor through Structure-Based Drug Design. J Med Chem 2000; 43:3482–3486PubMedCrossRefGoogle Scholar
  5. Beaumont K, Webster R, Gardner I, and Dack K. Design of Ester Prodrugs to Enhance Oral Absorption of Poorly Permeable Compounds: Challenges to the Discovery Scientist. Curr Drug Metab 2003; 4:461–485PubMedCrossRefGoogle Scholar
  6. Belshe, RB, Burke E, Newman F, Cerruti RL, and Sim IS. Resistance of Influenza A Virus to Amantidine and Rimatidine: Result of One Decade of Surveillance. J Infect. Dis 1989; 159:430–435PubMedGoogle Scholar
  7. Brooks MJ, Sasadeusz JJ, and Tannock GA. Antiviral Chemotherapeutic Agents against Respiratory Viruses: Where Are We Now and What’s in the Pipeline? Curr Opin Pulm Med 2004; 10:197–203PubMedCrossRefGoogle Scholar
  8. Cass LM, Efthymiopoulos C, and Bye A. Pharmacokinetics of Zanamivir after Intravenous, Oral, Inhaled or Intranasal Administration to Healthy Volunteers. Clin Pharmacokinet 1999; 36(Suppl. 1):1–11PubMedCrossRefGoogle Scholar
  9. Couch AB. Advances in Influenza Virus Vaccine Research. Ann NY Acad Sci 1993; 685:803–812PubMedCrossRefGoogle Scholar
  10. Dreitlein WB, Maratos J, and Brocavich J. Zanamivir and Oseltamivir: Two New Options for the Treatment and Prevention of Influenza. Clin Ther 2001; 23:327–355PubMedCrossRefGoogle Scholar
  11. Eisenberg E J, Bidgood A, and Cundy KC, Penetration of GS4071, A Novel Influenza Neuraminidase Inhibitor, Into Rat Bronchoalveolar Lining Fluid Following Oral Administration of the Prodrug GS4104. Antimicrob Agents Chemother 1997; 41:1949–1952PubMedGoogle Scholar
  12. Gubareva LV, Schallon D, and Hayden FG, Activity of the Neuraminidase Inhibitor RWJ-270201 (BCX-1812) against Influenza A and B Viruses in the Neuraminidase Inhibition Assays. II International Symposium on Influenza and other Respiratory Viruses. Dec. 10–12, 1999, Grand CaymanGoogle Scholar
  13. Hayden FG, Osterhaus AD, Treanor JJ, Fleming DM, Aoki FY, Nicholson KG, Bohnen AM, Hirst HM, Keene O, and Wightman K. Efficacy and Safety of the Neuraminidase Inhibitor Zanamivir in the Treatment of Influenza Virus Infections. N Engl J Med 1997; 337:874–880PubMedCrossRefGoogle Scholar
  14. He G, Massarella J, and Ward P. Clinical Pharmacokinetics of the Prodrug Oseltamivir and its Active Metabolite Ro 64-0802. Clin Pharmacokinet 1999; 37:471–484PubMedCrossRefGoogle Scholar
  15. Kati WM, Montgomery D, Carrick R, Gubareva L, Maring C, McDaniel K, Steffy K, Molla A, Hayden F, Kempf D, and Kohlbrenner W. In Vitro Characterization of A-315675, a Highly Potent Inhibitor of A And B Strain Influenza Virus Neuraminidases and Influenza Virus Replication. Antimicrob Agents Chemother. 2002; 46:1014–1021PubMedCrossRefGoogle Scholar
  16. Kim CU, Lew W, Williams MA, Liu H, Zhang L, Swaminathan S, Bischofberger N, Chen MS, Mendel DB, Tai CY, Laver WG, and Stevens RC, Influenza Neuraminidase Inhibitors Possessing a Novel Hydrophobic Interaction in the Enzyme Active Site: Design, Synthesis, and Structural Analysis of Carbocyclic Sialic Acid Analogues with Potent Anti-Influenza Activity, J Am Chem Soc 1997; 119:681–690PubMedCrossRefGoogle Scholar
  17. Leneva IA, Roberts N, Govorkova EA, Goloubeva OG, and Webster RG. The Neuraminidase Inhibitor GS4104 (Oseltamivir Phosphate) is Efficacious against A/Hong Kong/156/97 (H5N1) and A/Hong Kong/1074/99 (H9N2) Influenza Viruses. Antivir Res 2000; 48:101–115PubMedCrossRefGoogle Scholar
  18. Langmuir AD, Worthen TD, Solomon J, Ray CG, and Peterson E. Thucydides Syndrome: A New Hypothesis for the Cause of the Plague of Athens. N Engl J Med 1985; 313:1027–1030PubMedGoogle Scholar
  19. Leinweber F-J. Possible Physiological Roles of Carboxylic Ester Hydrolases. Drug Metab Dispos 1987; 16:425–428Google Scholar
  20. Li W, Escarpe PA, Eisenberg EJ, Cundy KC, Sweet C, Jakeman KJ, Merson J, Lew Williams M, Zhang L, Kim CU, Bischofberger N, Chen MS, and Mendell DB. Identification of GS 4104 as an Orally Bioavailable Prodrug of the Influenza Virus Neuraminidase Inhibitor GS 4071. Antimicrob. Agents Chemother 1998; 42:647–653PubMedCrossRefGoogle Scholar
  21. Lui KJ, and Kendal AP. Impact of Influenza Epidemics on Mortality in the United States from October 1972 to May 1985. Am J Public Health1987; 77:712–716PubMedGoogle Scholar
  22. McCauley JW, Pullen LA, Forsyth M, Penn CR, and Thomas GP. 4-Guanidino-Neu5Ac2en Fails to Protect Chickens from Infection with Highly Pathogenic Avian Influenza Virus. Antivir Res 1995; 27:179–186PubMedCrossRefGoogle Scholar
  23. Naem S. The Role of Neuraminidase Inhibitors in the Treatment and Prevention of Influenza. J Biomed Biotechnol 2001; 1:89–90CrossRefGoogle Scholar
  24. Palese P, and Compans RW. Inhibition of Influenza Virus Replication in Tissue Culture by 2-Deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): Mechanism of Action. Gen Virol 1976; 33:159–163CrossRefGoogle Scholar
  25. Pilcher H. Increasing Virulence of Bird Flu Threatens Mammals. Nature 2004; 430:434Google Scholar
  26. Rohloff JC, Kent KM, Postich MJ, Becker MW, Chapman HH, Kelly DE, Lew W, Louie MS, McGee LR, Prisbe EJ, Schultze LM, Yu RH, and Zhang LJ. Practical Total Synthesis of the Anti-influenza Drug GS-4104. J Org Chem 1998; 63:4545–4550CrossRefGoogle Scholar
  27. Stella VJ, Charman WNA, and Naringrekar VH. Prodrugs: Do They Have Advantages in Clinical Practice? Drugs 1985; 29:455–473PubMedCrossRefGoogle Scholar
  28. Sturm-Ramirez KM, Ellis T, Bousfield B, Bissett L, Dyrting K, Rehg JE, Poon L, Guan Y, Peiris M, and Webster RG. Reemerging H5N1 Influenza Viruses in Hong Kong in 2002 Are Highly Pathogenic to Ducks. J Virol 2004;7:4892–4901CrossRefGoogle Scholar
  29. Tumpey TM, Garcia-Sastre A, Mikulasova A, Taubenberger JK, Swayne DE, Palese P, and Basler CF. Existing Antivirals Are Effective against Influenza Viruses with Genes from the 1918 Pandemic Virus. Proc Natl Acad Sci. USA 2002; 99:13849–13854PubMedCrossRefGoogle Scholar
  30. von Itzstein M, Wu W-Y, Kok GK, Pegg MS, Dyason JC, Jin B, Van Phan T, Smithe ML, White HF, Oliver SW, Colman PM, Varghese JN, Ryan DM, Woods JM, Bethell RC, Hotham VJ, Cameron JM, and Penn CR. Rational Design of Potent Sialidase-Based Inhibitors of Influenza Virus Replication. Nature 1993; 363:418–423CrossRefGoogle Scholar
  31. Wood ND, Aitken M, Sharp S, and Evison H. Tolerability and Pharmacokinetics of the Influenza Neuraminidase Inhibitor Ro 64-0802 (GS4071) following Oral Administration of the Prodrug Ro 64-0796 (GS4104) to Healthy Male Volunteers. In: Program and Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, DC; 1997:A-123:125Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2007

Authors and Affiliations

  • Eugene J. Eisenberg
    • 1
  1. 1.Drug Metabolism DepartmentGilead Sciences, Inc.Foster CityUSA

Personalised recommendations